 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- || valproic acid/prednisone (VAL001) / Respiratorius, olumacostat glasaretil (DRM01) / Eli Lilly
BioStock: Sista personen doserad i Respiratorius PK-studie med VAL001 https://t.co/QZ3bokV4Dx (Twitter) - Jul 4, 2022
- || valproic acid/prednisone (VAL-001) / Respiratorius, olumacostat glasaretil (DRM01) / Eli Lilly
BioStock: Respiratorius inleder produktion av VAL001 https://t.co/bNtg0TNtH9 (Twitter) - Oct 14, 2021
- || valproic acid/prednisone (VAL-001) / Respiratorius, olumacostat glasaretil (DRM01) / Eli Lilly
BioStock: Respiratorius begins production of VAL001 https://t.co/2VeJkx6cjz (Twitter) - Oct 14, 2021
- || valproic acid/prednisone (VAL-001) / Respiratorius, olumacostat glasaretil (DRM01) / Eli Lilly
BioStock: Respiratorius gets patent approval in Brazil for VAL001 https://t.co/Pkmclrr4SO (Twitter) - Sep 30, 2021
- || methylprednisolone / generics
Clinical, Review, Journal: Early diagnosis improving the outcome of an infant with epileptic encephalopathy with cytoplasmic FMRP interacting protein 2 mutation: Case report and literature review. (Pubmed Central) - Nov 18, 2019
OUR: case confirmed that CYFIP2 was the pathogenic gene of EIEE 65. We also first demonstrated vigabatrin might be effective for control of seizures and helpful for the improved outcomes of these patients.
- | Rituxan (rituximab) / Roche
Trial completion, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Mar 12, 2018
P1/2, N=50, Completed, Sponsor: Lund University Hospital
We also first demonstrated vigabatrin might be effective for control of seizures and helpful for the improved outcomes of these patients. Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Mar 7, 2017
P1/2, N=50, Active, not recruiting, Sponsor: Lund University Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Mar 2018
- Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=50, Active, not recruiting, Sponsor: Lund University Hospital
Trial primary completion date: Dec 2016 --> Mar 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Feb 17, 2016
P1/2, N=50, Recruiting, Sponsor: Lund University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Oct 2015 --> Jun 2016
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=50, Recruiting, Sponsor: Lund University Hospital
Trial primary completion date: Oct 2015 --> Jun 2016 Trial primary completion date: Jul 2015 --> Oct 2015
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=50, Recruiting, Sponsor: Lund University Hospital
Trial primary completion date: Jul 2015 --> Oct 2015 Trial primary completion date: Mar 2015 --> Jul 2015
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=50, Recruiting, Sponsor: Lund University Hospital
Trial primary completion date: Mar 2015 --> Jul 2015 Trial primary completion date: Dec 2014 --> Mar 2015
- Rituxan (rituximab) / Roche
New P1/2 trial, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jun 17, 2012
P1/2, N=50, Recruiting, Sponsor: Lund University Hospital